Biosimilars Market By Reports And Data
                     Biosimilars 
Market To Reach 
USD 44.56 
Billion By 2026
              Markett  Summary
High target disease prevalence, product launches, emerging market players, and drug development 
pressure on pharmaceuticals due to upcoming patent expiries are key factors contributing to high 
CAGR of Biosimilars during forecast period.
Market Size – USD 5.10 Billion in 2018, Market Growth - CAGR of 30.8%, Market Trends – Product 
launches and research for advanced Biosimilars 
According to the current analysis of Reports and Data, the global Biosimilars market was valued at 
USD 5.10 Billion in 2018 and is expected to reach USD 44.56 Billion by year 2026, at a CAGR of 
30.8%. Biosimilar are alternatives to existing patented, and approved biologicss and possess similar 
medicinal properties as compared to the original biologics. The biosimilars vary a little from original 
biologics in terms of structure but must have similar safety and efficacy as compared to the 
originator biologics. Biosimilars development does not require Phase II clinical trial for approval 
and the focus is put on determination of ‘biosimilarity’ to the reference originator biologics. Thus it 
has much reduced clinical development timelines and reduced product costs as compared to use of 
original biologics.
www.reportsanddata.com
Further key findings from the report suggest
• Recombinant Peptides segment was estimated to account for USD 501.00 million in 2018 and is 
expected to grow reach USD 4.38 Billion by year 2026.
• As of 2018, Recombinant Non-glycosylated Proteins is the dominating Biosimilars which holds 
over 60% of the global market. European regional market is the chief revenue generating source 
for this product segment, followed by North America and Asia-Pacific regions.
• Biosimilars market is growing at a CAGR of 2% in Asia Pacific followed by North America and 
Europe, with 21.0% and 31.4% CAGR, respectively. High chronic disease prevalence across the 
globe is the key factor to accelerate the market growth during forecast period across all regions.
• Recombinant Glycosylated Proteins is expected to be the fastest growing market segment during 
forecast period 2019-2026 with a CAGR of 33.4%. However, regulatory obstacles and 
manufacturing complexity are major challenge for the market growth of this market segment.
• Some regions such as U.S. and Latin America are facing slow adoption of biosimilars due to 
stringent regulatory framework..
              Markett  Summary
Key Players:   
Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Samsung Biologics, Sandoz, Stada Arzneimittel, and 
Teva Pahrmaceutical.
Segmentation:
For the purpose of this report, Reports and Data has segmented the Biosimilars market on the basis of type, disease 
type, and region:
Type (Revenue, USD Million; 2016–2026)
• Recombinant Non-glycosylated Proteins
Disease Type (Revenue, USD Million; 2016–2026)
• Oncology
• Blood Disorders
• Chronic Diseases
• Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Other Diseases
To look at the PDF Sample Report and get 30 minutes of a free consultation @ https://
www.reportsanddata.com/sample-enquiry-form/1177
www.reportsanddata.com
              Markett  Summary
Disease Type (Revenue, USD Million; 2016–2026)
• Oncology
• Blood Disorders
• Chronic Diseases
• Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Other Diseases
Regional Outlook (Revenue in USD Million; 2016–2026)
• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America
Grab Your Report at an Impressive Discount! Please Click Here :  https://
www.reportsanddata.com/discount-enquiry-form/1177
www.reportsanddata.com
              The  reportt  emphasiizes  tthe  ffollllowiing  key  questtiions::
Q.1.What are the most lucrative and promising growth prospects for the market?
Q.2.Which sectors are expected to deliver a high growth rate and which industry aspects 
come into play in this advancement?
Q.3.Which geographies are estimated to exhibit the highest growth and the underlying 
causes?
Q.4.Which factors are impacting the future of the market and what are the driving 
factors?
Q.5.What are the hurdles and challenges curtailing the industry’s growth in the forecast 
period?
www.reportsanddata.com
About Us
Reports and Data is a market research and consulting company that provides 
syndicated research reports, customized research reports, and consulting services. 
Our solutions purely focus on your purpose to locate, target and analyze consumer 
behavior shifts across demographics, across industries and help client’s make a 
smarter business decision. We offer market intelligence studies ensuring relevant 
and fact-based research across a multiple industries including Healthcare, 
Technology, Chemicals, Power, and Energy. We consistently update our research 
offerings to ensure our clients are aware about the latest trends existent in the 
market. Reports and Data has a strong base of experienced analysts from varied 
areas of expertise.
Contact Us:
John Watson
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]